Merus Labs International Company Profile (TSE:MSL)

Analyst Ratings

Consensus Ratings for Merus Labs International (TSE:MSL) (?)
Ratings Breakdown: 2 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: C$3.15

Analysts' Ratings History for Merus Labs International (TSE:MSL)
Show:
DateFirmActionRatingPrice TargetActions
3/3/2016ScotiabankLower Price TargetSector PerformC$2.75 -> C$2.25View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2016Paradigm CapitalBoost Price TargetBuyC$2.10 -> C$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2016CormarkUpgradeSpeculative Buy -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2016TD SecuritiesLower Price TargetBuyC$4.50 -> C$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2016MackieBoost Price TargetHoldC$1.90 -> C$2.30View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2016Dundee SecuritiesBoost Price TargetBuyC$3.50 -> C$3.60View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2016Canaccord GenuityBoost Price TargetBuyC$3.00 -> C$4.25View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/30/2015CIBCInitiated CoverageSector OutperformerC$2.90View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/30/2015Royal Bank Of CanadaInitiated CoverageSector OutperformC$2.90View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/15/2015GMP SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/25/2015LaurentianBoost Price TargetBuyC$3.50 -> C$3.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/20/2014LB SecuritiesInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/19/2014Laurentian Bank of CanadaInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Merus Labs International (TSE:MSL)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Merus Labs International (TSE:MSL)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.01$0.03$0.02
Q2 20162($0.01)$0.00($0.01)
Q3 20161$0.02$0.02$0.02
Q4 20162$0.01$0.02$0.02
Q1 20172$0.01$0.02$0.02
Q2 20172$0.01$0.02$0.02
Q3 20173$0.02$0.03$0.03
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Merus Labs International (TSE:MSL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Merus Labs International (TSE:MSL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/11/2016Andrew PatientInsiderBuy10,000C$1.90C$19,000.00Tweet This Trade  Share This Trade on StockTwits
12/10/2015Barry FishmanDirectorBuy100,000C$1.72C$172,270.00Tweet This Trade  Share This Trade on StockTwits
12/10/2015Robert MclayInsiderBuy6,000C$0.00C$0.00Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Merus Labs International (TSE:MSL)
DateHeadline
07/25/16 05:25 PMCoverage Initiated on Healthcare Stocks Valeant Pharma, Merus Labs, Nobilis Health, and Concordia - Baystreet.ca
07/25/16 07:57 AMCoverage Initiated on Healthcare Stocks Valeant Pharma, Merus Labs, Nobilis Health, and Concordia -
07/19/16 09:53 AMHow Many Merus Labs International Inc (TSE:MSL)'s Analysts Are Bearish? - Press Telegraph
07/15/16 07:38 AMMerus Labs International, Inc. breached its 50 day moving average in a Bearish Manner : MSL-CA : July 15, 2016 -
07/05/16 05:04 PMMerus Announces Reduced Leverage and Provides Business Update - Yahoo Finance
07/05/16 09:50 AMForm 6-K Merus Labs International For: Jun 30
07/04/16 10:02 AMHow Analysts Feel About Merus Labs International Inc (TSE:MSL)? - Press Telegraph
07/01/16 08:05 AMMerus Labs Appoints Two New Senior Executives - PR Newswire (press release)
06/30/16 05:37 PMBRIEF-Merus Labs International says Michael Bumby appointed CFO
06/27/16 09:35 AMWere Analysts Bullish Merus Labs International Inc (TSE:MSL) This Week? - Press Telegraph
06/24/16 05:13 PMMerus Labs, A Specialty Pharmaceutical Company On the Rise, CEO Clip Video
06/16/16 05:25 PMMERUS LABS INTERNATIONAL INC T.MSL
05/04/16 08:20 AMMerus Labs International, Inc. breached its 50 day moving average in a Bearish Manner : MSL-CA : May 4, 2016 -
04/22/16 07:42 AMMerus Labs International, Inc. breached its 50 day moving average in a Bullish Manner : MSL-CA : April 22, 2016 -
04/01/16 07:16 AMMerus Labs International, Inc. breached its 50 day moving average in a Bullish Manner : MSL-CA : April 1, 2016 -
03/16/16 12:17 PMMerus Labs International, Inc. – Value Analysis (TORONTO:MSL) : March 16, 2016 -
03/15/16 07:18 AMMerus Labs International, Inc. breached its 50 day moving average in a Bullish Manner : MSL-CA : March 15, 2016 -
03/07/16 06:56 AMMerus Completes Acquisition of Surgestone®, Provames®, Tredemine® and Speciafoldine® Rights from Sanofi - [CNW Group] - Merus Completes Acquisition of Surgestone®, Provames®, Tredemine® and Speciafoldine® Rights from Sanofi
03/04/16 07:45 AMMerus Labs International, Inc. breached its 50 day moving average in a Bullish Manner : MSL-CA : March 4, 2016 -
03/01/16 08:05 AMMerus Labs International Inc. Announces Closing Of $27 Million Bought Deal Financing - [PR Newswire] - The Company will use its best efforts to file a prospectus supplement further to its base shelf prospectus dated October 30, 2015 in order to qualify the issuance of the Underlying Shares upon conversion of the Special Warrants in Canada. The prospectus supplement will be filed following the filing of a business acquisition report by the Company in connection with the acquisition of products from UCB Pharma on February 4, 2016. The Special Warrants will automatically convert into common shares upon the earlier of (i) the third business day following the filing of the prospectus supplement, and (ii) the date that is four months and one day from the date of the closing of the Offering. The Company leverages its expertise and commercial platform in Europe, Canada and select other markets to deliver value.
02/26/16 09:51 AMWere Analysts Bullish Merus Labs International Inc (TSE:MSL) This Week? - Stock Caller - Were Analysts Bullish Merus Labs International Inc (TSE:MSL) This Week?Stock CallerOut of 11 analysts covering Merus Labs International (TSE:MSL), 10 rate it “Buy”, 0 “Sell”, while 2 “Hold”. This means 83% are positive. Merus Labs International was the topic in 10 analyst reports since August 6, 2015 according to StockzIntelligence Inc.and more »
02/23/16 06:30 AMMerus Announces Inaugural Deal with Sanofi - [PR Newswire] - "We have acquired nine established products over the last ten months and continue to leverage our scalable commercial platform in Europe" stated Barry Fishman, Chief Executive Officer. Merus acquired the product rights for a one-time payment of €22.5 million.
02/19/16 06:58 AMMerus announces $27 million bought deal - [PR Newswire] - The proceeds of the Offering, together with an advance under the Company's amended and restated credit facility announced on February 1, 2016, will be used to fund a prospective acquisition of four pharmaceutical products in a key European market. The proposed transaction is with a top 10 global pharmaceutical company. The Company has not yet entered into a definitive agreement in connection with the acquisition and there is no assurance that the acquisition will be concluded. If the acquisition is not concluded within 60 days of issuance of the Subscription Receipts, or 90 days at the election of one of the co-lead Underwriters, on behalf of the Underwriters, then the Subscription Receipts will be cancelled and the funds held in escrow returned to the investors.
02/13/16 08:01 PMWere Analysts Bearish Merus Labs International Inc (TSE:MSL) This Week? - Sonoran Weekly Review - The Vista VoiceWere Analysts Bearish Merus Labs International Inc (TSE:MSL) This Week?Sonoran Weekly ReviewOut of 12 analysts covering Merus Labs International (TSE:MSL), 11 rate it “Buy”, 0 “Sell”, while 1 “Hold”. This means 92% are positive. Merus Labs International was the topic in 10 analyst reports since August 6, 2015 according to StockzIntelligence Inc.Merus Labs International Inc (TSE:MSL) Receives Average Rating of "Buy" from AnalystsIntercooler Financialall 6 news articles »
02/12/16 01:29 PMMerus Labs Reports Solid Fiscal Q1 2016 Results - PR Newswire (press release) - Merus Labs Reports Solid Fiscal Q1 2016 ResultsPR Newswire (press release)In fiscal Q1 2016, the Company incurred a net loss of $0.9 million compared to a net loss of $0.2 million for the prior year period. Revenues for the quarter were $15.9 million, earnings before interest, taxes, depreciation and amortization ("EBITDA ...and more »
02/11/16 03:05 PMMerus Labs Reports Solid Fiscal Q1 2016 Results - [CNW Group] - Merus Labs Reports Solid Fiscal Q1 2016 Results
02/11/16 01:21 PMTSXV-Listed Legend Power Systems Announces CFO, Board Appointment (CVE:LPS) - WallStreet.org - TSXV-Listed Legend Power Systems Announces CFO, Board Appointment (CVE:LPS)WallStreet.org... the resource, finance and technology sectors. He is currently the Chief Financial Officer of Marret Resource Corp., (MAR.TO), and also serves as a member of the board of directors (and chairman of the audit committee) of Merus Labs International ...and more »
02/11/16 06:07 AMQ1 2016 Merus Labs International Inc Earnings Release - After Market Close -
02/10/16 01:21 PMMerus Completes Acquisition of rights from UCB, Announces Q1 2016 Earnings Release Date - Merus Labs International Inc. (TSX:MSL, NASDAQ:MSLI) announced has completed the previously announced acquisition of rights to Elantan®, Isoket® and Deponit® in Europe and select other markets from UCB.
02/09/16 12:46 PMAnticipated EPS Decline for Merus Labs International Inc (MSL) - WallStreet.org - Anticipated EPS Decline for Merus Labs International Inc (MSL)WallStreet.orgWall Street await Merus Labs International Inc (TSE:MSL) to release earnings on February, 10. After releasing $0.01 EPS for the previous quarter, Merus Labs International Inc's analysts now forecasts -200.00% negative EPS growth. The stock closed at $1 ...Merus Labs International Inc (MSL) to Release Quarterly Earnings on ThursdayDaily Politicalall 5 news articles »
02/04/16 05:03 PMMerus completes acquisition of Elantan®, Isoket® and Deponit® rights from UCB and announces date of Q1 2016 earnings release - [PR Newswire] - Merus also announced today that it will release its fiscal earnings for the first quarter of fiscal 2016 after market close on Thursday, February 11, 2016. Merus will hold a conference call at 8:30am ET on Friday, February 12, 2016 to discuss the results. The Company leverages its expertise and commercial platform in Europe, Canada and select other markets to deliver value.
02/02/16 12:02 PMMT Newswires Stocks To Watch: Merus Labs, Rare Element Resources (NYSE:RES) - WallStreet.org - MT Newswires Stocks To Watch: Merus Labs, Rare Element Resources (NYSE:RES)WallStreet.orgMerus Labs International Inc. (MSL.TO, MSLI) – which gained near 10% on the TSX yesterday – has entered into an agreement with UCB to acquire rights to Elantan, Isoket and Deponit in Europe and select other markets. A statement said these products ...and more »
02/01/16 07:05 PMMerus Reaches Agreement to Acquire Three Cardiovascular Products - PR Newswire (press release) - Merus Reaches Agreement to Acquire Three Cardiovascular ProductsPR Newswire (press release)1, 2016 /PRNewswire/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] announced today that it has entered into an agreement with UCB to acquire rights to Elantan®, Isoket® and Deponit® in Europe and select other ...and more »
02/01/16 02:12 PMIIROC Trade Resumption - MSL -
02/01/16 01:52 PMMerus Reaches Agreement to Acquire Three Cardiovascular Products - [PR Newswire] - The acquisition will be funded with cash-on-hand and a new Euro-denominated five year term debt facility (matching where the majority of the product revenue will occur) at an interest rate of 4.5 percent per annum, decreasing as the Company de-leverages. The new Euro-denominated term debt facility was advanced under an amendment and restatement to the Company's existing credit agreement. All of the Company's obligations under the amended facility are guaranteed by all material subsidiaries of the Company and are secured by the material assets of the Company and the assets of, and all equity interests in its material subsidiaries.
02/01/16 01:27 PMIIROC Trading Halt - MSL -
12/09/15 08:18 AMMerus Labs International, Inc. breached its 50 day moving average in a Bearish Manner : December 9, 2015 -
12/07/15 03:05 PMMerus Reports Fiscal 2015 Results and Provides Business Update - [PR Newswire] - TORONTO, Dec. 7, 2015 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] is pleased to report its financial results for fiscal year ending September 30, 2015. The increase is related to a full year of sales compared with less than one month in the prior year.
12/07/15 06:07 AMQ4 2015 Merus Labs International Inc Earnings Release - After Market Close -
12/01/15 04:00 PMMerus Labs to Host Conference Call on Year End Results - [PR Newswire] - Merus Labs is a specialty pharmaceutical company focused on acquiring established products. Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of Section 21E (i) (1) of the United States Securities Exchange Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Merus' actual results to be materially different from any future results expressed or implied by these statements.
11/20/15 08:19 AMMerus Labs International, Inc. breached its 50 day moving average in a Bullish Manner : November 20, 2015 -
11/20/15 07:15 AMMerus Labs International (MSLI) Jumps: Stock Rises 6.4% -
10/21/15 06:30 PMMerus Labs Announces Filing of Audited June 30, 2015 Financial Statements - [PR Newswire] - TORONTO, Oct. 21, 2015 /PRNewswire/ - Merus Labs International Inc. (" Merus " or the " Company ") , announced today that it has filed on SEDAR the audited financial ...
09/09/15 07:37 AMWhat Falling Estimates & Price Mean for Merus Labs International (MSLI) -
08/25/15 12:03 PMMerus Labs International, Inc. Q3 Earnings, 2015 -
08/10/15 06:00 PMMerus Labs Reports Q3 2015 Results - [CNW Group] - Merus Labs Reports Q3 2015 Results

Social

About Merus Labs International

Merus Labs International logoMerus Labs International Inc. (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women's health and anti-infectives. Its products include Factive, Emselex/Enable and Vancocin. Enablex (darifenacin) or Emselex is used in treatment of urinary urgency and incontinence. Vancocin is used in treatment of C. difficile infection (CDI). Factive (Gemifloxacin Mesylate tablets) is the only Food and Drug Administration approved quinolone with five day oral dosing indicated for the treatment of both acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: TSE
  • Symbol: MSL
  • CUSIP:
Key Metrics:
  • Previous Close: $1.71
  • 50 Day Moving Average: $1.64
  • 200 Day Moving Average: $1.82
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $175.44M
  • Current Year EPS Consensus Estimate: $-0.02 EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links:
Merus Labs International (TSE:MSL) Chart for Tuesday, July, 26, 2016